Director Karen Firestone of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) recently completed a substantial purchase of the company's common stock. The transaction details, filed via a Form 4 with the Securities and Exchange Commission, indicate that Ms. Firestone acquired $51,338 worth of shares on May 21, 2026.
Specifically, the filing shows that Firestone purchased 3,800 shares of Amylyx common stock at a price point of $13.51 per share. Following this direct acquisition, Ms. Firestone's personal holdings in Amylyx Pharmaceuticals common stock now total 66,900 shares.
This insider buying activity takes place against the backdrop of recent market performance for AMLX. The stock is currently trading near $13.68, reflecting a substantial return of 155% over the past year. Furthermore, analysis from InvestingPro provides context on the company's financial standing, noting that while it maintains a 'Fair' financial health rating, the balance sheet shows cash reserves exceeding outstanding debt.
Recent Corporate and Clinical Developments
In other corporate news, Amylyx Pharmaceuticals recently reported its first-quarter 2026 earnings. The company posted a loss per share of $0.37 for the quarter. This figure was below the consensus analyst projection, which had anticipated a loss of $0.33 per share. Management noted that this quarterly result came alongside increased operating expenses.
Despite the recent financial metrics, the company continues to highlight its research progress. Amylyx Pharmaceuticals announced that data from its Phase 2 HELIOS trial concerning AMX0035 in Wolfram syndrome has been published within The Journal of Clinical Investigation. The results reported from this trial indicated continued improvements in pancreatic beta cell function observed through Week 48 across the twelve adult participants.
Market Context and Analysis
The market data provided shows AMLX trading at $13.68, representing a modest increase of $0.100 or 0.74% on the day of reporting. The stock's performance over various time frames has been tracked, including the last week (1W), month (1M), six months (6M), and one year (1Y).
The analysis also points to valuation tools, such as a Fair Value calculator that utilizes a combination of 17 proven industry valuation models to estimate potential intrinsic worth. The platform suggests that investors can look into identifying undervalued stocks for potentially significant upside.